XML 65 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
License agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Feb. 28, 2018
USD ($)
Jan. 08, 2018
$ / shares
Dec. 31, 2017
USD ($)
[1]
Related Party Transaction [Line Items]            
Long term investment   $ 165,972       $ 134,356
Research and development expense   303,103 $ 407,920      
Unrealized gain (loss) on long term investments   22,679 $ (5,814)      
Syros Pharmaceuticals, Inc.            
Related Party Transaction [Line Items]            
Number of program targets | item 7          
Upfront payment under license agreement $ 10,000          
Long term investment   $ 12,200        
Ownership percentage (as a percent)   3.00%        
Unrealized gain (loss) on long term investments   $ 3,200        
Syros Pharmaceuticals, Inc. | Stock purchase agreement            
Related Party Transaction [Line Items]            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.8          
Purchase price of common stock $ 10,000          
Per share price | $ / shares $ 12.61       $ 9.77  
Lock-up period 12 months          
Discount for lack of marketability $ 100          
Fair value of shares on the issuance date 7,600          
Long term investment 7,600          
Research and development expense $ 2,400          
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement            
Related Party Transaction [Line Items]            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.1          
Purchase price of common stock $ 1,400          
Per share price | $ / shares $ 9.55          
Long term investment       $ 1,400    
Syros Pharmaceuticals, Inc. | Maximum            
Related Party Transaction [Line Items]            
Target selection and option exercise fee payment $ 54,000          
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum            
Related Party Transaction [Line Items]            
Additional milestone payments under the license agreement 50,000          
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum            
Related Party Transaction [Line Items]            
Additional milestone payments under the license agreement $ 65,000          
[1] The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.